Nanobiotix (France) Performance
| NANO Stock | EUR 3.45 0.11 3.29% |
The company secures a Beta (Market Risk) of -0.79, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Nanobiotix are expected to decrease at a much lower rate. During the bear market, Nanobiotix is likely to outperform the market. At this point, Nanobiotix SA has a negative expected return of -0.22%. Please make sure to verify Nanobiotix's total risk alpha, maximum drawdown, skewness, as well as the relationship between the treynor ratio and potential upside , to decide if Nanobiotix SA performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nanobiotix SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 119.2 M | |
| Total Cashflows From Investing Activities | -242 K |
Nanobiotix |
Nanobiotix Relative Risk vs. Return Landscape
If you would invest 395.00 in Nanobiotix SA on November 8, 2024 and sell it today you would lose (61.00) from holding Nanobiotix SA or give up 15.44% of portfolio value over 90 days. Nanobiotix SA is generating negative expected returns and assumes 3.2609% volatility on return distribution over the 90 days horizon. Simply put, 29% of stocks are less volatile than Nanobiotix, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Nanobiotix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nanobiotix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nanobiotix SA, and traders can use it to determine the average amount a Nanobiotix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0683
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NANO |
Estimated Market Risk
| 3.26 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Nanobiotix is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nanobiotix by adding Nanobiotix to a well-diversified portfolio.
Nanobiotix Fundamentals Growth
Nanobiotix Stock prices reflect investors' perceptions of the future prospects and financial health of Nanobiotix, and Nanobiotix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nanobiotix Stock performance.
| Return On Equity | -1.99 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (17.96) % | |||
| Current Valuation | 111.08 M | |||
| Shares Outstanding | 34.88 M | |||
| Price To Earning | (12.17) X | |||
| Price To Book | 71.98 X | |||
| Price To Sales | 48.04 X | |||
| Revenue | 10 K | |||
| EBITDA | (44.85 M) | |||
| Cash And Equivalents | 36.2 M | |||
| Cash Per Share | 1.85 X | |||
| Total Debt | 35.56 M | |||
| Debt To Equity | 144.00 % | |||
| Book Value Per Share | 0.05 X | |||
| Cash Flow From Operations | (29.87 M) | |||
| Earnings Per Share | (1.20) X | |||
| Total Asset | 101.77 M | |||
| Retained Earnings | (17 M) | |||
| Current Asset | 23 M | |||
| Current Liabilities | 7 M | |||
About Nanobiotix Performance
By analyzing Nanobiotix's fundamental ratios, stakeholders can gain valuable insights into Nanobiotix's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nanobiotix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nanobiotix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Nanobiotix SA, a late stage clinical company, develops and sells nanomedicine for the treatment of cancer worldwide. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France. NANOBIOTIX operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. It employs 102 people.Things to note about Nanobiotix SA performance evaluation
Checking the ongoing alerts about Nanobiotix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nanobiotix SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nanobiotix SA generated a negative expected return over the last 90 days | |
| Nanobiotix SA has high historical volatility and very poor performance | |
| Nanobiotix SA has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the revenue of 10 K. Net Loss for the year was (47 M) with profit before overhead, payroll, taxes, and interest of 2.65 M. | |
| Nanobiotix SA has accumulated about 36.2 M in cash with (29.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.85. |
- Analyzing Nanobiotix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nanobiotix's stock is overvalued or undervalued compared to its peers.
- Examining Nanobiotix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nanobiotix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nanobiotix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nanobiotix's stock. These opinions can provide insight into Nanobiotix's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Nanobiotix Stock analysis
When running Nanobiotix's price analysis, check to measure Nanobiotix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobiotix is operating at the current time. Most of Nanobiotix's value examination focuses on studying past and present price action to predict the probability of Nanobiotix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobiotix's price. Additionally, you may evaluate how the addition of Nanobiotix to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |